Astellas Pharma Inc. (YPH.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 09:43PM CEST
| Previous Close | 13.05 |
| Open | 12.88 |
| Bid | 0.00 x 80000 |
| Ask | 0.00 x 70000 |
| Day's Range | 12.88 - 12.90 |
| 52 Week Range | 12.44 - 15.61 |
| Volume | |
| Avg. Volume | 234 |
| Market Cap | 23.621B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 34.85 |
| EPS (TTM) | 0.37 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.48 (3.70%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | N/A |
ZacksNew Strong Sell Stocks for September 26th
ALPMY, ASH and DHC have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2023.
Business WirePADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
BOTHELL, Wash. & TOKYO, September 22, 2023--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab) versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has spread to surrounding organs or muscles, or other
ZacksNew Strong Sell Stocks for September18th
ALPMY, CBRE and FMAO have been added to the Zacks Rank #5 (Strong Sell) List on September 18, 2023.
© 2023 Yahoo. All rights reserved.
